Capital Impact Advisors LLC increased its position in Assembly Biosciences Inc (NASDAQ:ASMB) by 15.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,988 shares of the biopharmaceutical company’s stock after buying an additional 6,306 shares during the quarter. Capital Impact Advisors LLC’s holdings in Assembly Biosciences were worth $1,747,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of Montreal Can purchased a new position in shares of Assembly Biosciences in the second quarter worth $145,000. Jane Street Group LLC purchased a new position in shares of Assembly Biosciences in the first quarter worth $204,000. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences in the second quarter worth $282,000. Barclays PLC increased its stake in shares of Assembly Biosciences by 220.5% in the first quarter. Barclays PLC now owns 8,189 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 5,634 shares during the period. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of Assembly Biosciences in the second quarter worth $348,000. 65.28% of the stock is currently owned by institutional investors.
Shares of Assembly Biosciences stock opened at $23.35 on Friday. The firm has a market cap of $643.29 million, a price-to-earnings ratio of -9.69 and a beta of 0.79. Assembly Biosciences Inc has a 12-month low of $23.05 and a 12-month high of $67.36.
Several research analysts recently commented on ASMB shares. Zacks Investment Research downgraded shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 13th. ValuEngine downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 3rd. B. Riley raised shares of Assembly Biosciences from a “neutral” rating to a “buy” rating and set a $42.00 target price on the stock in a research note on Monday, October 8th. Robert W. Baird initiated coverage on shares of Assembly Biosciences in a research report on Wednesday, August 8th. They set an “outperform” rating and a $74.00 price objective on the stock. Finally, BidaskClub downgraded shares of Assembly Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, July 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $62.60.
In other Assembly Biosciences news, insider Uri A. Lopatin sold 15,540 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $40.09, for a total transaction of $622,998.60. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 18.20% of the stock is currently owned by insiders.
Assembly Biosciences Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Read More: Asset Allocation and Your Retirement
Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences Inc (NASDAQ:ASMB).
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.